pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

6,918 products tracked · 6,918 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
  • Preclinical
    MIRA-55
    Anxiety Disorders$MIRA MIRA PHARMACEUTICALS, INC.
  • Phase 2
    MIT-001
    Oral Mucositis MitoImmune Therapeutics Inc
  • MITOXANTRONE
    MITOXANTRONE
    no indication HOSPIRA
  • Phase 2
    MIV-711
← prev
page 108 of 231
next →
131
Pain89
Neurology1
Osteoarthritis
Medivir AB
  • MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT
    MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE)
    no indication SpecGx LLC
  • Phase 3
    MK-1406
    Pandemic Influenza$MRK Merck & Co., Inc.
  • Phase 2
    MK-2214
    Alzheimer's Disease$MRK Merck & Co., Inc.
  • Phase 2
    MK-3795
    Von Hippel-Lindau Syndrome$MRK Merck & Co., Inc.
  • Phase 2
    MK-6194
    Ulcerative Colitis$MRK Merck & Co., Inc.
  • Marketed
    ML-061
    Docivyx (docetaxel)
    Adenocarcinoma Of The Gastroesophageal Junction Meridian Laboratories Inc
  • Preclinical
    MLN-33
    Melanoma$CNBX CNBX Pharmaceuticals Inc.
  • Phase 2
    MNV-101
    Pearson Syndrome Minovia Therapeutics Ltd
  • Phase 2
    MNV-201
    Pearson Syndrome Minovia Therapeutics Ltd
  • Phase 1
    MO-03
    Metastatic Renal Cell Carcinoma Osel Inc
  • Phase 1
    MOMA-313
    Metastatic Breast Cancer Moma Therapeutics Inc
  • Preclinical
    MOMA-989
    Unspecified Cancer Moma Therapeutics Inc
  • MOMETASONE FUROATE MONOHYDRATE
    MOMETASONE FUROATE MONOHYDRATE
    no indication AUROBINDO PHARMA
  • MONTELUKAST
    MONTELUKAST
    no indication MACLEODS PHARMS LTD
  • Phase 2
    MORF-057
    Crohn's Disease (Regional Enteritis) Eli Lilly and Co
  • MOXIFLOXACIN OPHTHALMIC SOLUTION
    MOXIFLOXACIN OPHTHALMIC SOLUTION
    no indication ALEMBIC
  • Preclinical
    MP-004
    Retinitis Pigmentosa (Retinitis) MIRAMOON Pharma SL
  • Phase 2
    MP-0712
    Neuroendocrine Tumors$MOLN MOLECULAR PARTNERS AG
  • Phase 2
    MP-101
    dimiracetam [INN]
    Amyotrophic Lateral Sclerosis Mitochon Pharmaceuticals Inc
  • Phase 2
    MP-1032
    Coronavirus Disease 2019 (COVID-19) MetrioPharm AG
  • Phase 2
    MPB-1734
    Solid Tumor MegaPro Biomedical Co Ltd
  • Preclinical
    MPB-2354
    Rheumatoid Arthritis MegaPro Biomedical Co Ltd
  • Phase 2
    MRG-002
    Gastric Cancer Shanghai Miracogen Inc
  • Phase 2
    MRG-004A
    Solid Tumor Shanghai Miracogen Inc
  • Phase 2
    MRM-3379
    Fragile X Syndrome$MIRM Mirum Pharmaceuticals, Inc.
  • Phase 2
    MRT-2359
    Metastatic Castration-Resistant Prostate Cancer (mCRPC)$GLUE Monte Rosa Therapeutics, Inc.